The future of drug discovery is human—with advances in organ-on-a-chip technologies like AIM Biotech’s idenTx line, the drawbacks of still relying on animal studies for pre-clinical data become more apparent with each new drug study. While expensive animal studies lead to a high rate of failure transitioning to the clinical stage, organ-on-a-chip tech offers more predictive, human-based data—and that’s just one reason why it stands poised to make animal studies a thing of the past. Drug Discovery & Development has published an insightful article about this very trend, featuring AIM Biotech’s technology as a case study. Check the piece out here, or click below:
Gathering more predictive, human-relevant data is what AIM Biotech is all about. Want to discuss how idenTx can transform your drug discovery research? Use the chat bubble on the bottom right corner of this page, and we’ll reach out to you—or check out our Contact Us page. Also be sure to look at how our contract research services can help streamline your workflow.